A Rare Case of Bilateral Primary B-Cell Non-Hodgkin Lymphoma of Breast

Primary B-Cell Non-Hodgkin Lymphoma of Breast is a rare presentation of breast malignancy and it is necessary to differentiate it from secondary breast lymphoma as prognosis and treatment varies based on the diagnosis. We report a case of 47-year-old female with bilateral PBNHL of Breast which is rare due to younger age of presentation than earlier reported cases of this malignancy, lump with “peau de orange” appearance seen in both the breasts which is usually seen with high grade lymphoma and complete recovery of the patient while bilateral PBL outlines poor prognosis. Mammosonography findings included dilated ducts with hypoechoiec areas. MRI showed altered signal intensity. Findings of the imaging studies are non-specific and vary widely from case to case which is why biopsy which is gold standard was done to confirm the diagnosis

Download Full-text

A Rare Case of Bilateral Primary B-Cell Non Hodgkin Lymphoma of Breast

10.21203/rs.3.rs-502417/v1 ◽

2021 ◽

Author(s):

Maharshi Romelbhai Raval ◽

Yash Patel ◽

Suchi D. Shah ◽

Kishan Gautam Patel ◽

Kamal Sharma

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Poor Prognosis ◽

Complete Recovery ◽

Imaging Studies ◽

Rare Presentation ◽

Breast Malignancy ◽

Non Hodgkin Lymphoma ◽

Breast Lymphoma ◽

Younger Age

Abstract Primary B-Cell Non Hodgkin Lymphoma of Breast is a rare presentation of breast malignancy and it is necessary to differentiate it from secondary breast lymphoma as prognosis and treatment varies based on the diagnosis. We present a case of 47-year-old female with bilateral PBNHL of Breast which is rare due to younger age of presentation than earlier reported cases of this malignancy, lump with “peau de orange” appearance seen in both the breasts which is usually seen with high grade lymphoma and complete recovery of the patient while bilateral PBL outlines poor prognosis. Mammosonography findings included dilated ducts with hypoechoiec areas. MRI showed altered signal intensity. Findings of the imaging studies are non-specific and vary widely from case to case which is why biopsy which is gold standard was done to confirm the diagnosis.

Download Full-text

Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma

Blood ◽

10.1182/blood-2011-03-340885 ◽

2011 ◽

Vol 118 (10) ◽

pp. 2809-2820 ◽

Cited By ~ 78

Author(s):

Zhi-Zhang Yang ◽

Deanna M. Grote ◽

Steven C. Ziesmer ◽

Michelle K. Manske ◽

Thomas E. Witzig ◽

...

Keyword(s):

T Cells ◽

B Cell ◽

Hodgkin Lymphoma ◽

Cd4 T Cells ◽

Poor Prognosis ◽

Elevated Serum ◽

Foxp3 Expression ◽

Soluble Form ◽

Activated T Cells ◽

Non Hodgkin Lymphoma

Abstract Elevated serum levels of the soluble form of IL-2 receptor α (sIL-2Rα) have been correlated with a poor prognosis in a variety of different types of cancers. However, its biologic relevance remains unclear and controversial. In patients with follicular B-cell non-Hodgkin lymphoma (FL), we observed that serum sIL-2Rα levels were elevated compared with controls and that elevated sIL-2Rα levels before treatment were associated with a poor outcome. To explore the mechanism by which sIL-2Rα may contribute to a poor prognosis in FL, we determined the effects of sIL-2Rα on IL-2 signaling and found that the sIL-2Rα–IL-2 complex promoted T-cell differentiation toward to inhibitory Treg cells rather than TH1 or TH17 cells. Shed by activated T cells that express membrane-bound IL-2Rα, sIL-2Rα further enhanced IL-2–mediated phosphorylation of Stat5 thereby significantly up-regulating Foxp3 expression in CD4+ T cells. We found that CD4+ T cells treated with either IL-2 or sIL-2Rα–IL-2 complex, but not with sIL-2Rα alone, inhibited the function of CD8+ T cells. Taken together, these results indicate that sIL-2Rα actually plays an active biologic role in FL by binding IL-2 and promoting IL-2 signaling rather than depleting IL-2 and blocking its function.

Download Full-text